Zanamivir

From Proteopedia

proteopedia linkproteopedia link

Revision as of 11:11, 12 December 2010 (edit) David Canner (Talk | contribs) ← Previous diff		Revision as of 11:12, 12 December 2010 (edit) (undo) David Canner (Talk | contribs) Next diff →
Line 4:		Line 4:
	* Major Indication: [[Influenza]] Infection		* Major Indication: [[Influenza]] Infection
	* Drug Class: [[Neuraminidase]] Inhibitor		* Drug Class: [[Neuraminidase]] Inhibitor
-	* Date of FDA Approval (Discontinued):	+	* Date of FDA Approval:
	* 2004 Sales:		* 2004 Sales:
	* Importance:		* Importance:

---

Revision as of 11:12, 12 December 2010

spinqualitylabelsall models Zanamivir, better known as Relenza, ([[____]]) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

Better Known as: Relenza

• Marketed By:
• Major Indication: Influenza Infection
• Drug Class: Neuraminidase Inhibitor
• Date of FDA Approval:
• 2004 Sales:
• Importance:
• See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

Neuraminidase Inhibitor Pharmacokinetics Parameter Zanamivir Oseltamivir Tmax (hr) 1.25 1.5 Cmax (ng/ml) 31.6 57 Bioavailability (%) 2 75 Protein Binding (%) 10 42 T1/2 (hr) 3 3.2 AUC (ng/ml/hr) 185 204 Clearance (L/h) 54.1 18.8 Dosage (mg) 10 300 Metabolism None Hepatic For References to Pharmacokinetic data, see: References

References